Education
About Us
Working with TipRanks
Follow Us
Apyx Medical (DE:BOV)
:BOV
BOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.72 - €1.75
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€29.57M
Enterprise Value€67.53M
Total Cash (Recent Filing)$2.64M
Total Debt (Recent Filing)$5.06M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 08, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,793,884
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.99
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-3.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Apyx Medical News
PremiumCompany Announcements
Apyx Medical Reports 2024 Financial Results and Strategic Plans
PremiumCompany Announcements
Apyx Medical’s Mixed Earnings Call: Opportunities and Challenges
PremiumCompany Announcements
Apyx Medical Appoints New Chief Operating Officer
---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentThe company announced the 510k submission of the Ayon body contouring system, which encompasses a wide range of therapeutic offerings.
Technology InnovationRenuvion is viewed as a differentiated helium-based plasma technology that can save significant time and provide superior clinical outcomes in several large, high-growth surgery markets.
Bears Say
Financial PerformanceAPYX fell short of its revenue covenants mandated by its credit agreement with Perceptive Advisors due to the previously mentioned transient macro factors.
Macroeconomic ChallengesDemand for aesthetic capital equipment and procedures has contracted, reflecting a challenging macroeconomic environment.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.81% Insiders
10.27%
Mutual Funds
1.76% Other Institutional Investors
82.20% Public Companies and
Individual Investors
BOV FAQ
What was Apyx Medical’s price range in the past 12 months?
Apyx Medical lowest stock price was €0.71 and its highest was €1.75 in the past 12 months.
What is Apyx Medical’s market cap?
Apyx Medical’s market cap is €29.57M.
When is Apyx Medical’s upcoming earnings report date?
Apyx Medical’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were Apyx Medical’s earnings last quarter?
Apyx Medical released its earnings results on Mar 13, 2025. The company reported -€0.106 earnings per share for the quarter, beating the consensus estimate of -€0.141 by €0.035.
Is Apyx Medical overvalued?
According to Wall Street analysts Apyx Medical’s price is currently Overvalued.
Does Apyx Medical pay dividends?
Apyx Medical does not currently pay dividends.
What is Apyx Medical’s EPS estimate?
Apyx Medical’s EPS estimate is -0.11.
How many shares outstanding does Apyx Medical have?
Apyx Medical has 37,793,884 shares outstanding.
What happened to Apyx Medical’s price movement after its last earnings report?
Apyx Medical reported an EPS of -€0.106 in its last earnings report, beating expectations of -€0.141. Following the earnings report the stock price went up 2.186%.
Which hedge fund is a major shareholder of Apyx Medical?
Currently, no hedge funds are holding shares in DE:BOV
---
Apyx Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.86%
12-Months-Change
Fundamentals
Return on Equity
-114.70%
Trailing 12-Months
Asset Growth
-18.17%
Trailing 12-Months
Company Description
Apyx Medical
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
---
BOV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there were several positive developments such as strong advanced energy segment performance, successful marketing campaigns, and cost-saving initiatives, the decline in overall revenue, OEM segment sales, and international revenue, coupled with market challenges from GLP-1 drug adoption, present notable challenges.Read More>---
BOV Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering BOV
1 Year
1 Year Success Rate
3/29 ratings generated profit
1 Year Average Return
-30.89%
reiterated a buy rating 14 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 10.71% of your transactions generating a profit, with an average return of -30.89% per trade.
---